Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Belite Bio wraps up Phase III trial of Stargardt disease treatment

Summary by Clinical Trials Arena
Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the Tinlarebant.The post Belite Bio wraps up Phase III trial of Stargardt disease treatment appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

ophthalmologytimes.comophthalmologytimes.com
Reposted by
modernretina.commodernretina.com

Belite Bio concludes phase 3 DRAGON study for Stargardt disease

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Belite Bio wraps up Phase III trial of Stargardt disease treatment

Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the Tinlarebant.The post Belite Bio wraps up Phase III trial of Stargardt disease treatment appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Monday, September 15, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal